The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 4 ( October-December, 2022 ) > List of Articles


Malignant Pleural Effusion: A Continued Relevance of Closed Needle Pleural Biopsy

Abhishek Gupta, Unnati Desai, Jyotsna M. Joshi

Keywords : Malignant pleural effusion, Mesothelioma, Metastatic adenocarcinoma, Percutaneous closed needle pleural biopsy

Citation Information : Gupta A, Desai U, Joshi JM. Malignant Pleural Effusion: A Continued Relevance of Closed Needle Pleural Biopsy. Indian J Chest Dis Allied Sci 2022; 64 (4):288-291.

DOI: 10.5005/jp-journals-11007-0037

License: CC BY-NC 4.0

Published Online: 05-01-2023

Copyright Statement:  Copyright © 2022; The Author(s).


Introduction: Thoracocentesis and pleural biopsy are recommended for the evaluation of undiagnosed exudative pleural effusion. There are multiple etiologies associated with them, out of which malignancy is one of them. Hence, the diagnosis of malignant pleural effusion (MPE) has been proposed in recent perspectives. We aimed to find the profile of MPE, efficacy of percutaneous closed needle pleural biopsy (PCNPB) in diagnosing MPE, overall yield, and complication rate to evaluate the continued relevance of this traditional procedure. Methods: This was a prospective study carried out on consecutive consenting patients at the Department of Pulmonary Medicine at a tertiary care hospital from July 2016 to May 2018. The diagnosis was based on cytobiochemical, microbiological, and histopathological results along with clinical history. Data were analyzed with respect to pleural fluid assessment in terms of cytobiochemical and microbiological evaluation; while pleural biopsy was studied histopathologically. Results: Two hundred and fifty patients with exudative pleural effusion were enrolled. Tuberculosis (218, 87.2%) was the most common etiology followed by malignancy (22, 8.8%). The most common presenting complaint was chest pain (100%) followed by dyspnea (90.47%). Metastatic adenocarcinoma was found in 81.81% followed by mesothelioma in 18.18%. The sensitivity of pleural biopsy for malignancy was found to be 63.63% (p < 0.003, odds ratio [OR]: 2.01), and those fulfilling Leung's criteria, sensitivity was found to be 90.90% (p < 0.001, OR: 3.67). The sensitivity of pleural fluid for malignancy was 18.18% (p < 0.05, OR: 1.51). All cases of mesothelioma have asbestos exposure. The complication in the form of mild post-pleural biopsy pain was encountered in 10%, which required mild analgesics. Other complications in the form of self-resolving pneumothorax were seen in 6%, which increased hospital stay to 2–3 days and self-resolving hematoma (3%). Conclusion: In this modern era, PCNPB still holds high sensitivity, efficacy rate, and relevance for diagnosing MPE with less complication rate, less hospital stay, and can be done on a daycare basis. Also, we have very less research and paperwork regarding this topic.

PDF Share
  1. Light RW. The undiagnosed pleural effusion. Clin Chest Med 2006;27(2):309–319. DOI: 10.1016/j.ccm.2005.12.002.
  2. Maskell NA, Butland RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003;58:ii8-17. DOI: 10.1136/thorax.58.suppl_2.ii8.
  3. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J 2001;18(2):402–419. DOI: 10.1183/09031936.01.00225601.
  4. Sconfienza LM, Mauri G, Grossi F, et al. Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy. Radiology 2013;266(3):930–955. DOI: 10.1148/radiol.12112077.
  5. Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. Am J Roentgenol 1990;154(3):487–492. DOI: 10.2214/ajr.154.3.2106209.
  6. Koss MN, Fleming M, Przygodzki RM, et al. Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases. Ann Diagn Pathol 1998;2(2):93–102. DOI: 10.1016/s1092-9134(98)80045-2.
  7. Awasthi A, Gupta N, Srinivasan R, et al. Cytopathological spectrum of unusual malignant pleural effusions at a tertiary care centre in north India. Cytopathology 2007;18(1):28–32. DOI: 10.1111/j.1365-2303.2007.00382.x.
  8. Gupta A, Utpat K, Desai U, et al. Pseudomesotheliomatous adenocarcinoma related pleural effusion-contemplate the differential! J Evid Based Med Healthc 2018;5(26): 2009–2011. DOI:10.18410/jebmh/2018/417.
  9. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985;56(4):905–909. PMID: 4016683.
  10. Lee YC, Light RW. Management of malignant pleural effusions. Respirology 2004;9(2):148–156. DOI: 10.1111/j.1440-1843.2004.00566.x.
  11. Tassi GF, Cardillo G, Marchetti GP, et al. Diagnostic and therapeutical management of malignant pleural effusion. Ann Oncol 2006;17:ii11-192. DOI: 10.1093/annonc/mdj911.
  12. Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med 2012;4:31–52. DOI: 10.2147/OAEM.S29942.
  13. Rice TW, Rodriguez RM, Barnette R, et al. Prevalence and characteristics of pleural effusions in superior vena cava syndrome. Respirology 2006;11(3):299–305. DOI: 10.1111/j.1440-1843.2006.00841.x.
  14. Maskell NA, Davies CW, Nunn AJ, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352(9):865–874. DOI: 10.1056/NEJMoa042473.
  15. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985;60(3):158–164. DOI: 10.1016/s0025-6196(12)60212-2.
  16. Morrone N, Algranti E, Barreto E. Pleural biopsy with Cope and Abrams needles. Chest 1987;92(6):1050–1052. DOI: 10.1378/chest.92.6.1050.
  17. Bhattacharya S, Bairagya TD, Das A, et al. Closed pleural biopsy is still useful in the evaluation of malignant pleural effusion. J Lab Physicians 2012;4(1):35–38. DOI: 10.4103/0974-2727.98669.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.